Who We Are
LaQuiliam is a medical technology company developing breakthrough oral diagnostic devices that harness advanced photonics to detect cancer and other mouth abnormalities with unprecedented precision. Our light based, non‑invasive technology is engineered to integrate seamlessly into routine dental and clinical examinations, giving clinicians a powerful tool to identify cancerous and precancerous cells earlier than traditional methods allow.
Designed to make early detection effortless and accessible, LaQuiliam devices prioritise patient comfort and clinical practicality while delivering laboratory grade results. By transforming ordinary exams into opportunities for timely intervention, we aim to improve outcomes, reduce invasive procedures, and raise the standard of care in oral health diagnostics.
LaQuiliam is building the next generation of technologies focused on early, non‑invasive detection of cancer and oral disease. Our research and development pipeline advances photonics, machine learning, and biomarker discovery to expand screening capabilities beyond visible lesions targeting molecular and cellular changes that precede clinical symptoms. These innovations are intended to bring faster, more accurate screening into everyday practice, enabling clinicians to act sooner and patients to receive less invasive, more effective care.
